Plus Therapeutics

01/08/2026

announces the completion of a Type B meeting with the U.S. Food and Drug Administration on next steps on pivotal strategy for (LM). The meeting resulted in constructive discussion with the regarding key elements of the potential pivotal study design for REYOBIQ in LM.

intends to incorporate this feedback in the current dose optimization trial and seek alignment with the FDA on a revised protocol, likely later this year. The company’s goal is to be ready for a potential pivotal trial following completion of the current dose optimization trial and, ultimately, work towards the potential approval of REYOBIQ for patients affected by LM.

Full press release here: bit.ly/4qc4WBL

More about REYOBIQ™: plustherapeutics.com/reyobiq

12/23/2025

will be closed, starting tomorrow until Friday, January 2nd.

Wishing everyone a peaceful and healthy holiday season from our entire team!

12/22/2025

Dr.Andrew Brenner gives an overview of (LM) along with the latest results from our RESPECT-LM (www.respect-trials.com/lm) presented at the San Antonio Breast Cancer Symposium earlier this month in his 2-part discussion with AJMC

Check out more of their video interview here: bit.ly/49ejGZQ

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.

12/18/2025

’ encouraging data presented at the 2025 San Antonio Breast Cancer Symposium represents a meaningful step forward in leptomeningeal metastases treatment options.

Andrew Brenner, MD, PhD, dives into the key takeaways from ’s presentations with AJMC in this video interview: https://bit.ly/4j5wVR0

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.

12/16/2025

Targeted represent a new generation of cancer therapies, combining powerful radioactive isotopes with precise delivery technologies designed to irradiate tumors directly while minimizing exposure to healthy tissue.

is advancing this approach with a focused mission to deliver safe, targeted internal radiation therapies for adults and children facing rare and difficult-to-treat cancers.

Drug Development & Delivery recently spoke with ’s President & CEO, Marc Hedrick, M.D., about our targeted platform and why internal radiation therapy may represent a more precise and patient-focused approach to cancer treatment.

Check out the full interview here: https://bit.ly/48XpZk2

More about targeted radiotherapeutics: https://bit.ly/4hxVXaI

12/15/2025

Thank you to those who stopped by Dr. Andrew Brenner’s oral and poster and oral presentation on ReSPECT phase 1 dose escalation results for at the San Antonio Breast Cancer Symposium ( ) last week, as well as each contributor and trial site for their continued efforts to push this crucial study forward.

View the full poster shared at on the website: bit.ly/4q5ttrF

Learn more about our RESPECT-LM trial here: www.respect-trials.com/lm

Andrew Brenner, MD, PhD, will share a poster and oral presentation on ' ReSPECT phase 1 dose escalation results for at the San Antonio Breast Cancer Symposium ( ) tomorrow morning.

Learn more about Dr. Brenner’s presentation at here: bit.ly/44AWymz

Learn more about our RESPECT-LM trial here: www.respect-trials.com/lm

12/11/2025

Andrew Brenner, MD, PhD, will share a poster and oral presentation on ' ReSPECT phase 1 dose escalation results for at the San Antonio Breast Cancer Symposium ( ) tomorrow morning.

Learn more about Dr. Brenner’s presentation at here: bit.ly/44AWymz

Learn more about our RESPECT-LM trial here: www.respect-trials.com/lm

12/11/2025

announces that it has been granted lab licenses to provide the ® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT) in California, Rhode Island and Maryland.

CNSide Diagnostics is now licensed in 48 U.S. States covering over 90% of the U.S. population.

Full press release here: bit.ly/494nxJM

Learn more about CNSide: cnside-dx.com

12/09/2025

today announced two new hires to its team for CNSide Diagnostics, its wholly-owned subsidiary.

Mr. Prem Gurnani joins as Senior Director of Lab Operations and Systems Implementation, bringing over sixteen years of experience in diagnostics, clinical operations, regulatory compliance, and technology driven process improvement across high growth healthcare organizations and laboratory environments, with a strong record supporting operational scale up.

Ms. Elaine Luckey joins as Director of Quality and Regulatory affairs, with over twenty years of experience in quality and regulatory affairs in CLIA/CAP laboratory environments and a track record in start-ups, quality system implementation and regulatory compliance.

Full press release here: bit.ly/3KlDKB7

12/05/2025

The move to Hines' Levit Green-Houston positions and CNSide Diagnostics within one of the fastest-growing biomedical hubs in the US. Located steps from the Texas Medical Center, the world’s largest medical complex, our new space provides:

- Advanced laboratory infrastructure
- Immediate access to world-class clinical and research institutions
- Proximity to leading oncology, neurology, and translational science programs
- A collaborative ecosystem for biotech and life sciences innovation

This location strengthens 's ability to accelerate the development of cutting-edge CNS oncology diagnostics and .

Read more: https://bit.ly/4iByaae

A life sciences-focused development near the TMC added a hat trick of tenants as local investment grows.

12/04/2025

announces three positive clinical data update presentations at the / Society for Neuro-Oncology’s Annual Meeting.

Key highlights below:

- Cohort 1 data from multiple dose ReSPECT- (LM) showed no dosage limiting toxicity

- ReSPECT- (GBM) trial of REYOBIQ as a novel therapeutic for recurrent demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation

- MRI combined with SPECT imaging biomarkers effectively evaluate overall survival response with in recurrent GBM treatment and help guide personalized patient planning

Full press release here: bit.ly/48u3TFG

Learn more about our RESPECT here: https://bit.ly/4oCGLux

12/03/2025

’ momentum in central nervous system (CNS) oncology was highlighted when our President & CEO, Marc Hedrick, MD, recently sat down with Ira Pastor on the Progress, Potential, And Possibilities podcast. The discussion is a sharp look at where is headed as we build a differentiated position in CNS .

In under an hour, Dr. Hedrick breaks down:
- Why (LM) and recurrent ( ) represent some of the clearest opportunities for targeted
- How Plus Therapeutics is shaping a focused, capital-efficient pipeline
- How their subsidiary, CNSide Diagnostics is creating a data advantage by identifying and characterizing tumor cells in the CSF, generating insights that strengthen LM management today while supporting the development and positioning of ™

This conversation offers a clear, candid view of the strategy, the science, and the market opportunity ahead for Plus and .

Listen/watch the full episode to learn more about our work and the future of CNS cancer innovation: https://bit.ly/48N7hwH

Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused...